Atypical Ductal Hyperplasia
Understanding Atypical Ductal Hyperplasia (ADH), a benign breast lesion with atypia? Learn about ADH diagnosis, clinical documentation, and medical coding for this precancerous breast condition. Find information on healthcare guidelines, pathology reports, and treatment options for atypical ductal hyperplasia.
Overgrowth of cells in breast ducts with some abnormal features, but not cancerous.
Usually found incidentally on mammogram or biopsy. No palpable lump or other symptoms.
Detected during breast cancer screening or evaluation of breast changes.
ICD-10 Code Families
Complete code families applicable to N60.3
When to use each related code
| Description | When to use |
|---|---|
| Abnormal cell growth in breast ducts, slightly increased risk of cancer. | ADH, atypical cells in breast ducts, not cancerous but requires follow-up. Benign breast biopsy result with atypia. |
| Usual Ductal Hyperplasia, overgrowth of cells lining breast ducts, low cancer risk. | UDH, increased cells in breast ducts, typically benign finding on biopsy. No atypia present. |
| Ductal Carcinoma In Situ, cancerous cells confined to breast ducts, high risk if untreated. | DCIS, malignant cells in breast ducts, non-invasive breast cancer. Stage 0 breast cancer. |
Best-practice checklist
- ✓ADH or Atypical Ductal Hyperplasia diagnosis documented
- ✓Microscopic description of atypia present
- ✓Location and size of ADH lesion specified
- ✓Correlation with imaging findings if available
- ✓ICD-10 code N60.82 for ADH assigned
Common pitfalls to avoid
Using non-specific ICD-10 codes like N60.89 for ADH instead of the more precise D05.12 can lead to inaccurate reporting and claims.
Misinterpreting ADH as a malignant condition or vice versa, affecting coding accuracy and patient care plans.
Insufficient clinical documentation specifying ADH vs other atypical hyperplasia can cause coding errors and compliance issues.
Best-practice tips
- 01Complete excision biopsy for accurate ADH diagnosis. ICD-10: N95.1
- 02Document atypia features for proper risk assessment. SNOMED: 419436002
- 03Close post-op surveillance to monitor for recurrence. CPT: 19120
- 04Correlate imaging findings with pathology report for clarity. CDI best practice
- 05Patient education on breast health and follow-up. Healthcare compliance
Step-by-step checklist
- 1
Confirm diagnosis via core needle biopsy pathology report (ICD-10 N60.89)
- 2
Document ADH features: cellular proliferation, architectural atypia (SNOMED CT 413828006)
- 3
Exclude DCIS: Verify absence of comedonecrosis, rigid architecture
- 4
Assess risk stratification: Consider family history, personal history of breast cancer
- 5
Recommend appropriate surveillance and management based on clinical guidelines (e.g., NCCN)
Ready-to-paste narrative
Patient presents with concerns regarding breast changes. Clinical breast exam reveals no palpable mass. Mammography demonstrates an area of architectural distortion prompting ultrasound-guided core needle biopsy. Pathology report confirms a diagnosis of atypical ductal hyperplasia (ADH), a benign breast lesion with atypia. The microscopic examination revealed proliferation of atypical cells within the breast ducts, but not meeting the criteria for ductal carcinoma in situ (DCIS). Differential diagnoses considered included fibroadenoma, papilloma, and other benign breast conditions. Given the increased risk of subsequent breast cancer associated with ADH, a comprehensive discussion regarding breast cancer risk factors, surveillance strategies including short-interval follow-up imaging, and prophylactic options such as chemoprevention was conducted. Patient understands the implications of this diagnosis and agrees to enhanced surveillance. ICD-10 code N60.89, other specified benign mammary dysplasia, is documented. CPT codes for the procedures performed, such as the biopsy (e.g., 19100) and imaging (e.g., 77067 for diagnostic mammography), are also recorded. A referral to a breast surgeon for consultation regarding surgical excision is recommended for risk reduction. Patient education materials on atypical ductal hyperplasia, breast cancer prevention, and surveillance guidelines were provided. Follow-up appointment scheduled in six months for repeat clinical breast exam and imaging.
Common questions and answers
What is the differential diagnosis for Atypical Ductal Hyperplasia (ADH) and how can I distinguish it from Ductal Carcinoma In Situ (DCIS) on a core needle biopsy?+
Atypical Ductal Hyperplasia (ADH) can be challenging to differentiate from Ductal Carcinoma In Situ (DCIS), particularly on a core needle biopsy. The key distinguishing feature lies in the extent of involvement within the duct. ADH demonstrates some, but not all, of the architectural and cytological features of DCIS. While both show abnormal cell growth within the breast ducts, ADH affects less than two ducts and the cell population displays less uniformity compared to DCIS. The architectural patterns (cribriform, micropapillary, solid) may be present, but the degree of cellular atypia and involvement is less extensive in ADH. Immunohistochemical markers, such as p16 and Ki-67, can sometimes assist in distinguishing between these lesions, but are not always definitive. Careful assessment of the extent of ductal involvement, cytological atypia, and architectural pattern is crucial for accurate diagnosis. When the distinction is uncertain on core biopsy, an excisional biopsy is often recommended to ensure complete assessment of the lesion and rule out DCIS. Explore how our comprehensive pathology review service can support complex breast biopsy diagnoses.
What is the recommended management strategy for Atypical Ductal Hyperplasia (ADH) considering its premalignant potential and risk of upgrade to invasive breast cancer?+
Atypical Ductal Hyperplasia (ADH) is considered a premalignant lesion, increasing the risk of developing both invasive breast cancer and DCIS in the same or opposite breast. While ADH itself isn't cancerous, it signifies an increased risk compared to the general population. Management typically involves surgical excision to ensure complete removal of the ADH and to rule out the presence of more advanced lesions, such as DCIS or invasive carcinoma, which may be present in the same area but missed on the initial core biopsy. Following excision, close surveillance with regular mammograms and clinical breast exams is recommended. The specific surveillance schedule may vary depending on individual risk factors, including family history of breast cancer and other contributing factors. Consider implementing risk-reducing strategies for patients diagnosed with ADH, such as chemoprevention with selective estrogen receptor modulators (SERMs) if appropriate, and counseling on lifestyle modifications known to impact breast cancer risk. Learn more about risk stratification and management strategies for patients with ADH.
A patient has been diagnosed with Atypical Ductal Hyperplasia (ADH) on a core needle biopsy. What are the key considerations in counseling this patient regarding prognosis and the next steps in management?+
When counseling a patient diagnosed with Atypical Ductal Hyperplasia (ADH) on core biopsy, it's vital to emphasize that ADH is not cancer but carries an increased risk of developing breast cancer in the future. Clearly explain the need for an excisional biopsy to fully assess the lesion and rule out more serious pathology. Discuss the potential outcomes of the excisional biopsy, including the possibility of finding DCIS or invasive carcinoma. Provide clear information about the purpose of the procedure, recovery process, and potential complications. Address the patient's concerns regarding the increased risk of breast cancer and discuss long-term surveillance plans, including regular mammograms and clinical breast exams. Provide information on risk-reducing strategies, including lifestyle modifications and the possibility of chemoprevention, tailored to the patient's individual risk profile. Encourage open communication and answer all questions thoroughly to alleviate anxiety and facilitate informed decision-making. Explore resources that can assist in patient education and support following an ADH diagnosis.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.